BELLUS Health reports topline results from its Phase 2 trial of BLU-5937, a P2X3 antagonist, for the treatment of chronic cough

BELLUS Health, a biopharmaceutical company developing therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced topline results from its Phase 2 RELIEF trial of BLU-5937 (a P2X3 antagonist) in patients with refractory chronic cough.

Disappointingly, this Phase 2 trial did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency. However, statistically significant placebo adjusted reductions in cough frequency was achieved in a pre-specified sub-group of high cough count patients.

BLU-5937 was well tolerated with no serious adverse events reported and with low impact on taste perception.

The company plans to move BLU-5937 forward into an adaptive Phase 2b trial enriched for higher cough count patients.

Read the press release here.

Read more about BELLUS Health here.

Photo by Online Marketing on Unsplash